Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Amy Mae Bunker is active.

Publication


Featured researches published by Amy Mae Bunker.


Bioorganic & Medicinal Chemistry Letters | 1996

1,3-DIARYL-2-CARBOXYINDOLES AS POTENT NON-PEPTIDE ENDOTHELIN ANTAGONISTS

Amy Mae Bunker; Jeremy J. Edmunds; Kent Alan Berryman; Donnelle M. Walker; Michael A. Flynn; Kathy M. Welch; Annette Marian Doherty

Abstract Endothelin-1 is a potent vasoconstrictor that is thought to be involved in many human disease states. We have developed a series of indole non-peptide endothelin antagonists including PD 159110 ( 31 ), an ET A selective antagonist, and PD 159020 ( 37 ), a non-selective ET A /ET B antagonist. The discovery, synthesis, and structure-activity relationships of this series of compounds are described.


Bioorganic & Medicinal Chemistry Letters | 1996

1-Benzyl-3-thioaryl-2-carboxyindoles as potent non-peptide endothelin antagonists

Amy Mae Bunker; Jeremy J. Edmunds; Kent Alan Berryman; Donnelle M. Walker; Michael A. Flynn; Kathy M. Welch; Annette Marian Doherty

Abstract Endothelin-1 is a potent vasoconstrictor which is thought to be involved in many human disease states. We have developed a series of indole non-peptide endothelin antagonists which display nanomolar receptor affinity. The representative compound from this series is PD 159433 ( 22 ), an ET A selective antagonist with an IC 50 of 2 nM. The discovery, synthesis and structure-activity relationships of this series of compounds are described.


Bioorganic & Medicinal Chemistry | 1998

Endothelin receptor antagonists: synthesis and structure–activity relationships of substituted benzothiazine-1,1-dioxides

Kent Alan Berryman; Jeremy J. Edmunds; Amy Mae Bunker; Stephen J. Haleen; J. Bryant; Kathy M. Welch; Annette Marian Doherty

The development of benzothiazine-1,1-dioxide derivatives as a new structural class of potent endothelin receptor antagonists is described. Structure-activity relationships (SAR) revealed that PD164800 (1) is a potent antagonist of the ETA receptor subtype.


Archive | 1997

Nonpeptide endothelin antagonists

Kent Alan Berryman; Amy Mae Bunker; Annette Marian Doherty; Jeremy John Edmunds


Journal of Medicinal Chemistry | 2000

Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors.

Danette Andrea Dudley; Amy Mae Bunker; Liguo Chi; Wayne L. Cody; Debra R. Holland; Diane P. Ignasiak; Nancy Janiczek-Dolphin; Thomas B. McClanahan; Thomas E. Mertz; Lakshmi Narasimhan; Stephen T. Rapundalo; Julia A. Trautschold; Chad A. Van Huis; Jeremy John Edmunds


Journal of Medicinal Chemistry | 1995

Derivatives of 5-[[1-(4'-carboxybenzyl)imidazolyl]methylidene]hydantoins as orally active angiotensin II receptor antagonists.

Jeremy J. Edmunds; Sylvester Klutchko; James Marino Hamby; Amy Mae Bunker; Connolly Cj; Winters Rt; Quin J rd; Ila Sircar; John C. Hodges; Robert L. Panek


Archive | 1996

Benzothiazine dioxides as endothelin antagonists

Kent Alan Berryman; Amy Mae Bunker; Annette Marian Doherty; Jeremy John Edmunds


Archive | 2001

Certain benzothiazine dioxide endothelin antagonists and processes for their preparation

Amy Mae Bunker; Xue-Min Cheng; Annette Marian Doherty; Jeremy John Edmunds; Gerald David Kanter; Chitase Lee; Joseph Thomas Repine; Richard W. Skeean


Journal of Medicinal Chemistry | 1993

Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-l-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]-methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H-imidazole-5-carboxylic acid (CI-996)

Ila Sircar; John C. Hodges; John Quin; Amy Mae Bunker; R.Thomas Winters; Jeremy J. Edmunds; Catherine R. Kostlan; Connolly Cj; Stephen J. Kesten


ChemInform | 2010

Nonpeptide Angiotensin II Receptor Antagonists. Part 2. Design, Synthesis, and Structure-Activity Relationships of 2-Alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole Derivatives: Profile of 2-Propyl-1-((2′-(1H-tetrazol-5-yl)-(1,1′-biphenyl)-4-yl

Ila Sircar; John C. Hodges; J. Iii Quin; Amy Mae Bunker; R. T. Winters; Jeremy J. Edmunds; Catherine R. Kostlan; Connolly Cj; Stephen J. Kesten; J. M. Hamby; J. G. Topliss; J. A. Keiser; R. L. Panek

Collaboration


Dive into the Amy Mae Bunker's collaboration.

Researchain Logo
Decentralizing Knowledge